Physician profile
Aaron A Wohl
NPI 1174636724
$1,053.76
in general payments reported to CMS, 2019-2025
21 companies · $15.78 in 2025
The $15.78 reported for 2025 was less than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.63 · 2020: $29.04 · 2021: $110 · 2022: $575 · 2023: $204 · 2024: $37.91 · 2025: $15.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $237 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $237.24 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $222.74 | 2022 | |
| Abbvie INC. | $219.06 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $83.78 | 2019-2023 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $69.51 | 2021-2023 | |
| Csl Behring | $43.54 | 2019-2024 | Kcentra |
| Teva Pharmaceuticals USA, INC. | $40.11 | 2022-2023 | Austedo |
| Otsuka America Pharmaceutical, INC. | $38.03 | 2023 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $34.45 | 2022 | |
| Allergan, INC. | $33.29 | 2019 | |
| Almatica Pharma LLC | $32.17 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $31.32 | 2022-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $30.71 | 2022-2023 | Quviviq |
| Neurocrine Biosciences, INC. | $27.34 | 2023 | Ingrezza |
| Corium, LLC | $23.44 | 2021 | |
| Indivior INC. | $19.94 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $19.88 | 2023 | Wellbutrin, Aplenzin |
| Alkermes, INC. | $19.16 | 2022 | |
| Tempus Ai, INC | $17.91 | 2024 | |
| Neos Therapeutics, LP | $16.39 | 2023 | Adzenys Xr-Odt |
| Stryker Corporation | $15.78 | 2025 | Flowtriever |
| E.R. Squibb & Sons, L.L.C. | $15.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Wohl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.